Qnovia to Showcase Innovative Nicotine Cessation Strategies at 2026 ATS Summit Qnovia will present groundbreaking nicotine cessation approaches at the 2026 ATS Respiratory Innovation Summit in Orlando, demonstrating their commitment to improved respiratory care.

Qnovia to Showcase Innovative Nicotine Cessation Strategies at 2026 ATS Summit #United_States #Orlando #Qnovia #Respiratory_Innovation #ATS_Summit

Qnovia's Innovative NRT Offers New Hope for Smokers in First Clinical Trial Qnovia has announced positive Phase 1 trial results for its inhaled nicotine replacement therapy, RespiRx™, potentially revolutionizing smoking cessation methods.

Qnovia's Innovative NRT Offers New Hope for Smokers in First Clinical Trial #United_States #Irvine #Qnovia #RespiRx #Nicotine_Replacement

Qnovia, Inc. Unveils Leadership Changes to Propel UK Market Strategy Qnovia, Inc. announces key leadership transitions including Mario Danek as CEO, aiming to boost its commercialization strategy in the UK.

Qnovia, Inc. Unveils Leadership Changes to Propel UK Market Strategy #United_States #Irvine #Qnovia #Mario_Danek #UK_strategy

Qnovia Launches Phase 1 Study for Innovative Nicotine Inhaler Targeting Smoking Cessation Qnovia, Inc. has initiated its Phase 1 clinical trial for the RespiRx™ Nicotine Inhaler, a groundbreaking approach to smoking cessation in the U.S.

Qnovia Launches Phase 1 Study for Innovative Nicotine Inhaler Targeting Smoking Cessation #USA #Richmond #Smoking_Cessation #Qnovia #RespiRx_Nicotine

Qnovia Secures $16 Million in Series B Financing to Enhance Nicotine Inhaler's Development Qnovia, Inc. has successfully raised $16 million in Series B financing aimed at advancing its RespiRx™ Nicotine Inhaler for smoking cessation.

Qnovia Secures $16 Million in Series B Financing to Enhance Nicotine Inhaler's Development #United_States #Richmond #Qnovia #RespiRx #Nicotine_Inhaler